Where is Merck & Co. (MRK) Headed According to Wall Street?

Merck & Co., Inc. (NYSE:MRK) is one of the best affordable healthcare stocks to buy now. Jefferies analyst Tycho Peterson reaffirmed a Buy rating on Merck & Co., Inc. (NYSE:MRK) on December 19 and set a $139.00 price target.

The same day, Merck & Co., Inc. (NYSE:MRK) announced a historic agreement with the Trump administration to ensure the affordability and accessibility of its medicines for Americans. The agreement allows the company to ensure that Americans have access to its life-changing vaccines and medications at lower costs.

Merck & Co., Inc. (NYSE:MRK) reported that it has plans to provide key products at affordable prices for eligible patients in the US through a direct-to-patient program, which currently includes JANUVIA, JANUMET, and JANUMET XR. The plan will be expanded in the future to include enlicitide decanoate after FDA approval. The direct-to-patient program would allow the availability of JANUVIA, JANUMET, and JANUMET XR to eligible American patients at a cash price, which reflects an approximately 70% discount from the current list price.

Management also reported that Merck & Co., Inc. (NYSE:MRK) reached an understanding with the U.S. Department of Commerce for the delay of Section 232 tariffs for three years, allowing the company to make investments in the United States to reshore manufacturing for American patients.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people. Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.